comparing cardiovascular and kidney outcomes with tirzepatide vs. glp-1 agonists Unveiling Tirzepatide's Therapeutic Spectrum: A Dual GIP/GLP-1 Agonist Targeting Metabolic, Neurological, Health Kidney Outcomes With Glucagon-Like Peptide-1

Glucagon-like peptide-1 and its class BG proteincoupled receptors: a long march to therapeutic successes

Hsia DS, Grove O, Cefalu WT

As we follow long-term outcomes of current therapies with new medications coming to market, it will be crucial to continue to evaluate lipid-specific outcomes that play a role in the overall cardiovascular benefits of GLP-1RA and other highly effective anti-obesity medications

Longitudinal monitoring of lipase and amylase in adults with type 2 diabetes and obesity: evidence from two phase 3 randomized clinical trials with the once-daily GLP-1 analog liraglutide [poster presentation at Digestive Disease Week 2012]

CMSK Pharma, Yabao/Pan-Jiayuan) are investing in generic peptide manufacturing or co-development, but mostly on smaller scales and often for regional markets

GLP-1 drugs produce dramatic, rapid weight loss by maintaining supraphysiological levels of synthetic GLP-1 in the bloodstream around the clock